Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658537 | 0.94 | ALDH1A1 (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL29641579 | 0.94 | ALDH1A1 (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL4658535 | 0.94 | ALDH1A1 (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL29562926 | 0.94 | ALDH1A1 (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL7619811 | 0.94 | ALDH1A1 (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL31438647 | 0.94 | ALDH1A1 (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL29906310 | 0.92 | ALDH1A1 (0.51) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL29353917 | 0.92 | ALDH1A1 (0.51) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051813 | 0.90 | ALDH1A1 (0.45) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051417 | 0.89 | ALDH1A1 (0.47) | ALDH1A1ENPEPL3MBTL1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-116496962-A | Pseudo uridine engineering bacterium, application thereof and method for producing pseudo uridine | 台州学院 | 2023-07-28 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | MME 824/4885ACE 1190/4885CPA1 245/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | MME 105/4885ACE 486/4885CPA1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.